Recombinant Human VEGFR1/Flt-1 Protein

Product Discontinued

Recombinant Human VEGFR1/Flt-1 Protein Summary

• Description: Recombinant bioactive protein for Human VEGFR1/Flt-1
  
  

  Source:Insect cells
  Amino Acid Sequence:(P17948) - MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRGEHC NKKAVFSRIS KFKSTRNDCT TQSNVKH

• Details of Functionality: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 ug/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
• Source: Baculovirus
• Protein/Peptide Type: Recombinant Protein
• Gene: FLT1
• Purity: >90%, by SDS-PAGE
• Endotoxin Note: <0.1 ng/ug

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • SDS-Page
• Theoretical MW: 96 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20 to -80C. Avoid freeze-thaw cycles.
• Buffer: Lyophilized from PBS.
• Concentration: Lyoph
• Purity: >90%, by SDS-PAGE
• Reconstitution Instructions: Reconstitute in water to no less than 0.1 mg/ml. This solution can then be stored at 4C for 2-7 days. For long term storage add a carrier protein (0.1 % HSA or BSA) and store at -20C. Avoid freeze-thaw cycles.

Alternate Names for Recombinant Human VEGFR1/Flt-1 Protein

• EC 2.7.10
• EC 2.7.10.1
• FLT
• FLT1
• Flt-1
• Fms-like tyrosine kinase 1
• fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor)
• FRT
• Tyrosine-protein kinase FRT
• Tyrosine-protein kinase receptor FLT
• vascular endothelial growth factor receptor 1
• Vascular permeability factor receptor
• VEGF R1
• VEGFR1
• VEGFR-1

Background

The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Soluble FLT1 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide containing 688 amino acids and having a molecular mass of 96 kDa. The soluble receptor protein contains only the first 6 extracellular domains, which contain all the information necessary for binding of VEGF. The FLT1 is purified by proprietary chromatographic techniques.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FLT1